| Added by | mollevi |
|---|---|
| Last modified by | pcoopman |
| Group name | EquipePC |
| Item Type | Journal Article |
| Title | Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network |
| Creator | Beau-Faller et al. |
| Author | M. Beau-Faller |
| Author | N. Prim |
| Author | A. M. Ruppert |
| Author | I. Nanni-Metellus |
| Author | R. Lacave |
| Author | L. Lacroix |
| Author | F. Escande |
| Author | S. Lizard |
| Author | J. L. Pretet |
| Author | I. Rouquette |
| Author | P. de Cremoux |
| Author | J. Solassol |
| Author | F. de Fraipont |
| Author | I. Bieche |
| Author | A. Cayre |
| Author | E. Favre-Guillevin |
| Author | P. Tomasini |
| Author | M. Wislez |
| Author | B. Besse |
| Author | M. Legrain |
| Author | A. C. Voegeli |
| Author | L. Baudrin |
| Author | F. Morin |
| Author | G. Zalcman |
| Author | E. Quoix |
| Author | H. Blons |
| Author | J. Cadranel |
| Abstract | BACKGROUND: There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS: EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network. RESULTS: Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], worse in smokers than in non-smoker patients with exon 20 mutations (12 versus 21 months; hazard ratio [HR] for death 0.27, 95% CI 0.08-0.87, P = 0.03). Under EGFR-tyrosine kinase inhibitors (TKIs), median OS was 14 months (95% CI 6-21); disease control rate was better for complex mutations (6 of 7, 86%) than for single mutations (16 of 40, 40%) (P = 0.03). CONCLUSIONS: Rare EGFR-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment. |
| Publication | Ann Oncol |
| Volume | 25 |
| Pages | 126-31 |
| Date | Jan 2014 |
| Journal Abbr | Annals of oncology : official journal of the European Society for Medical Oncology / ESMO |
| DOI | 10.1093/annonc/mdt418 |
| ISSN | 1569-8041 (Electronic) 0923-7534 (Linking) |
| Tags | Adenocarcinoma/drug therapy/*genetics/mortality, Adult, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics/mortality, clin, clinic, Disease-Free Survival, Drug Resistance, Neoplasm/genetics, Exons, Female, Gene Frequency, Genetic Association Studies, Humans, Lung Neoplasms/drug therapy/*genetics/mortality, Male, Middle Aged, Proportional Hazards Models, Protein Kinase Inhibitors/pharmacology/therapeutic use, Receptor, Epidermal Growth Factor/antagonists & inhibitors/*genetics, Young Adult |
| Date Added | 2018/11/14 - 12:07:50 |
| Date Modified | 2019/05/28 - 10:32:31 |
| Notes and Attachments | (Note) (Note) 24285021 (Attachment) |
Institut de Recherche en Cancérologie de
